WASHINGTON — The White House on Wednesday provided the clearest evidence yet that, eventually, some drug makers might not have to cut Medicaid the best deal on prescription drugs.
It would be a big win for drug makers, who say the current rules — which require every drug company to give Medicaid programs the lowest possible price, or “best price,” for any drug they sell — don’t give them the flexibility to test new payment ideas, like paying for drugs based on how well they work.
About the Author Reprints
